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Introduction {#sec001}
============

Seasonal influenza epidemics continue to have a substantial public health and economic burden in the United States. On average, it is estimated that over 200,000 people are hospitalized and 23,000 people die from respiratory and circulatory complications associated with seasonal influenza virus infections each year \[[@pone.0169344.ref001]--[@pone.0169344.ref007]\]. The annual direct medical costs have been found to average \$10.4 billion; indirect costs, which include estimated lost earnings due to illness and loss of life, average \$16.3 billion \[[@pone.0169344.ref005]\]. The total economic burden, using projected statistical life values of seasonal influenza epidemics, is estimated to be as high as \$87 billion each year.

The burden of illness caused by seasonal influenza varies by age and the presence of preexisting medical conditions. Serious medical complications leading to hospitalizations and deaths are typically greatest among persons aged 65 years and older, as has been shown previously with influenza-attributed hospitalization rates. High-risk persons aged 18 to 49, 50 to 64, and 65 and older illustrated rates of 4.0, 12.3, and 55.6, respectively, per 10,000 person-periods \[[@pone.0169344.ref004]\]; in contrast, rates among low-risk adults were 0.5, 1.8, and 18.7 per 10,000 person-periods, respectively.

Though the impact of seasonal influenza epidemics has been studied for the general population, there is a paucity of literature describing the burden of illness and associated costs attributed to this viral infection for the US Veterans Affairs population. The Veterans Health Administration of the Department of Veterans Affairs (VA) serves an older patient population that is predominantly male and has a higher disease burden than the general US population \[[@pone.0169344.ref008]\]. Leveraging previously described methodologies, the objective of this study was to estimate the economic impact of severe influenza-induced illness on US Veterans Affairs population over a five-year period from 2010 to 2014.

Materials and Methods {#sec002}
=====================

Study data {#sec003}
----------

This study used data from VA, which is the largest integrated healthcare system in the US and provides comprehensive health services to US Veterans. VA has an integrated and unified electronic medical record system (EMR) that contains information about inpatient, outpatient, and emergency department (ED) visits. This includes procedures, surgeries and diagnoses, pharmacy, laboratory results, extended care, vital signs, healthcare-related survey data and mortality for all persons treated within VA. Each patient is assigned a unique identification number that allows longitudinal follow-up.

VA uses a separate electronic Managerial Cost Accounting system (MCA) to capture the cost of healthcare services. Costs are not based on insurance claims, reimbursements or billing data; rather, they are the allocation of actual expenses (e.g. salaries, equipment, buildings, energy, negotiated drug prices, materials) to a specific healthcare encounter. Unlike claims data, such as those used by the Centers for Medicare and Medicaid Services, VA expense data are not subject to variation in coding practices. Data on Veteran mortality are likewise consistent, as VA Vital Status files incorporate information through multiple sources that include the National Death Index (NDI) and capture deaths that occur at VA, as well as non-VA locations, including at home or non-VA facilities.

The study observation period encompassed five respiratory seasons from 2010/11 through 2014/15 (simplified as 2010 to 2014). A respiratory season was defined as starting in calendar week 27 during a given year and ending in calendar week 26 of the following year. For example, respiratory season 2010/11 started June 27, 2010 and lasted through June 25, 2011. The study population was comprised of Veterans aged 18 and older enrolled at VA. To ensure we included those who received non-incidental care, patients were eligible for inclusion in a given respiratory season only if they had at least one inpatient or outpatient VA healthcare encounter during the prior respiratory season. Patients were classified into three groups for each season based on age, which was calculated at the end of the respiratory season or death: 18 to 49, 50 to 64, and 65 and older. Patients were also classified each season as at high-risk or at low-risk for influenza-related complications; this categorization was based on the presence of one or more primary International Classification of Diseases---9th edition (ICD-9-CM) diagnosis codes from an inpatient or outpatient encounter during the prior respiratory season. Patients assigned diagnosis codes for chronic cardiac, pulmonary, renal, metabolic, liver, or neurological diseases; diabetes mellitus; hemoglobinopathies; and/or immunosuppressive conditions and malignancy were at high-risk \[[@pone.0169344.ref004]\]. Patients for whom we did not find an encounter with one of these diagnosis codes ([S1 Table](#pone.0169344.s003){ref-type="supplementary-material"}) were classified as at low-risk.

This study was approved by the Veteran's Institutional Review Board of Northern New England (VINNE) through expedited review for the use of protected health information (PHI) as it was deemed to involve no more than minimal risk to the privacy of individuals (CPHS 28523). All study procedures were carried out in compliance with federal and institutional ethical standards as well as the Helsinki Declaration. The usual requirements for HIPAA authorization and study participants' written or verbal informed consent were waived by VINNE. Such waivers may be granted by regulatory committees when a research study meets all of the following criteria:

1.  The use or disclosure of the PHI involves no more than minimum risk to the privacy of individuals, based on, at least, the presence of all the following elements: An adequate plan to protect the identifiers from improper use and disclosure.An adequate plan to destroy the identifiers at the earliest opportunity consistent with conduct of research, unless there is a health or research justification for retaining the identifiers or such retention is otherwise required by law.Adequate written assurances that the PHI will not be reused or disclosed to any other person or entity, except as required by law, for authorized oversight of the research study, or for other research for which the use or disclosure of PHI would be permitted by the HIPAA Privacy Rule.

2.  The research could not practicably be conducted without the waiver or alteration.

3.  The research could not practicably be conducted without access to and use of the PHI.

Estimating influenza-attributed outcomes {#sec004}
----------------------------------------

Influenza-attributed outcomes were categorized as follows: (1) ED visit; (2) hospitalization; and (3) followed by death (all-cause or with underlying respiratory or circulatory causes). Similar to previously published research methods, a negative-binomial regression model was employed to generate weekly rates for each outcome category by risk and age group as the difference between the model-predicted outcomes and the model-predicted outcomes under the hypothetical absence of influenza (estimated baseline), which were then totaled over the length of the respiratory season \[[@pone.0169344.ref002]\]. Annual estimates were defined as rates per 100,000 person-periods (respiratory seasons) averaged over the five year study period. The regression model, fit using PROC GENMOD, SAS Enterprise Guide, version 6.1, with the dispersion parameter, was: $$\begin{array}{l}
{\text{Y} = \alpha exp\left\{ \beta_{0\ } + \beta_{1}t + {\ \beta}_{2}t^{2} + \beta_{3}t^{3} + \beta_{4}t^{4} + \beta_{5}t^{5} + {\ \beta}_{6}\text{cos}\left( \frac{2\pi t}{52} \right) + {\ \beta}_{7}\text{sin}\left( \frac{2\pi t}{52} \right) \right.} \\
\left. + {\ \beta}_{8}\left\lbrack {\text{A}\left( {\text{H}1\text{N}1} \right)} \right\rbrack + \beta_{9}\left\lbrack {\text{A}\left( {\text{H}3\text{N}2} \right)} \right\rbrack + {\ \beta}_{10}\left\lbrack {\text{A}\left( {\text{H}1\text{N}1_{2009}} \right)} \right\rbrack + \beta_{11}\left\lbrack \text{B} \right\rbrack + \beta_{12}\left\lbrack \text{RSV} \right\rbrack \right\} \\
\end{array}$$ where Y represents the weekly number of influenza-attributed outcomes (VA ED visits, VA hospitalizations or all-cause deaths) for each risk and age group, α the offset term (equals to the size of the risk and age group-specific population), β~0~ the intercept, β~1~ the linear time trend, β~2~ through β~5~ the non-linear time trend, β~6~ and β~7~ the seasonal changes in outcomes, β~8~ through β~11~ the weekly percentage of tests positive for each influenza virus type and subtype (*t*) and β~12~ the weekly percentage of tests positive for respiratory syncytial virus (RSV). Publicly available weekly influenza surveillance data, including RSV-specific surveillance data obtained directly from the CDC, were used in the model \[[@pone.0169344.ref009]\]. Additional parameter details are described in [S1 Table](#pone.0169344.s003){ref-type="supplementary-material"}.

To estimate excess VA ED visits and VA hospitalizations, only those healthcare encounters at a VA facility with a principal diagnosis of underlying respiratory or circulatory conditions (ICD-9-CM codes 390--519) were included in the model \[[@pone.0169344.ref006]--[@pone.0169344.ref007],[@pone.0169344.ref010]\]. The modeled excess deaths initially included those from all causes, and later was adjusted for underlying respiratory and circulatory causes based on a random sample with cause of death.

Estimating the cost per influenza-attributed encounter {#sec005}
------------------------------------------------------

For each influenza-attributed VA ED visit identified, direct medical costs were defined as the sum of the ED costs on the corresponding visit date, including expenses related to office visits, professional consults, prescription medications and laboratory tests, imaging and procedures performed.

VA hospitalizations were categorized by whether or not an episode of extended care followed the discharge. For each influenza-attributed VA hospitalization without extended care identified, direct medical costs were defined as the sum of the inpatient costs from the date of admission to the date of discharge at an acute care facility. For each influenza-attributed VA hospitalization with extended care identified, direct medical costs were defined as the sum of the inpatient, rehabilitation and/or skilled nursing facility costs if the extended care stay began immediately (within 24 hours) following the discharge from an acute care facility.

Direct medical costs for an influenza-attributed encounter defined above were extracted from VA MCA data for those events with a principal diagnosis of underlying influenza and pneumonia (ICD-9-CM codes 480--487) that occurred during each respiratory season \[[@pone.0169344.ref005]\]. Estimates of encounter-specific direct medical costs were calculated by risk and age group for each respiratory season; results are presented as the average over the five year study period.

Estimating the economic burden of seasonal influenza epidemics {#sec006}
--------------------------------------------------------------

Data from the US Department of Labor Bureau of Labor Statistics were used to estimate the annual economic burden of productivity loss due to the absence from work \[[@pone.0169344.ref011]\]. For hospitalizations, the annual estimate of outcome events was multiplied by the 2014 (most resent data available) mean Veteran occupation rates of 73.8%, 64.8%, and 18.8% for age groups 18 to 49, 50 to 64, and 65 and older, respectively; by the 2014 mean daily occupational wage of \$182; and by the mean length of stay in days for each risk and age group ([S1 Table](#pone.0169344.s003){ref-type="supplementary-material"}) \[[@pone.0169344.ref011]--[@pone.0169344.ref012]\]. For ED visits, a length of stay of one day was assumed. To estimate productivity loss caused by mortality, length of stay was replaced with a three month friction period \[[@pone.0169344.ref013]\].

To estimate the annual economic burden of influenza-attributed ED visits and hospitalizations, the annual estimate of outcome events was multiplied by the mean cost per outcome event for each risk and age group.

We used previously described methods to estimate the annual economic burden of influenza-attributed deaths \[[@pone.0169344.ref014]\]. Life years lost were derived for mortalities observed in the study population using US Department of Health and Human Services Life Tables \[[@pone.0169344.ref015]\]. Each life year lost was adjusted with the appropriate age- and gender-specific utility value to determine the all-cause quality-adjusted life years (QALYs) lost by patient; these were summed to annual totals for each risk and age group \[[@pone.0169344.ref016]\]. The all-cause QALYs lost were then multiplied by the proportion of estimated influenza-attributed deaths from the rates found through the modeling technique described above to determine influenza-attributed QALYs lost. Lastly, the value of influenza-attributed QALYs was calculated by multiplying the annual estimate of QALYs lost for each risk and age group with the value of \$150,000 per QALY \[[@pone.0169344.ref017]\].

Removal of outliers {#sec007}
-------------------

In order to further increase the accuracy of estimated medical costs attributable to influenza, and to reduce the impact that erroneous data and rare-but-extreme values might have on the estimates, we imposed restrictions to the dataset \[[@pone.0169344.ref018]\]. Outliers for length of stay and medical costs were excluded using statistical distributions equivalent to at least two standard deviations from the mean in a normal distribution. These calculated exclusion criteria are as follows: (1) ED visits which cost less than \$100 (below 1^st^ percentile) or more than \$1,500 (above 99^th^ percentile); (2) hospitalizations which cost less than \$2,000 (below 2^nd^ percentile) or more than \$95,000 (above 98^th^ percentile); (3) hospitalizations with a length of stay over 28 days (above 98^th^ percentile); and, (4) hospitalizations followed by extended care with a length of stay over 450 days (above 98^th^ percentile).

Respiratory or circulatory causes of death {#sec008}
------------------------------------------

Influenza-attributed all-cause mortality estimates, as generated from the analysis described above, include those that may not be directly associated with influenza, such as accidental deaths. To provide more accurate estimates, deaths were categorized as those with a respiratory or circulatory cause and those without; deaths with a cardiorespiratory cause are presumed to be more directly associated with influenza. Because cause of death was not available for the majority of deaths, we instead applied an adjustment to the all-cause mortality model, which involved multiplying the observed deaths per week by the average proportion of deaths per calendar week due to respiratory or circulatory conditions. The average proportion was calculated from a random sample of 13,000 VA enrolled Veterans for whom cause of death data were available from 2010 to 2014. Furthermore, by calculating the proportion per calendar week, we were able to account for seasonal variation in the cardiorespiratory proportion of all mortality.

Alternative values of QALY {#sec009}
--------------------------

Death associated with influenza is a major driver of the total annual economic burden on the US. Therefore, the impact of a range of valuations for the monetary value of a QALY on the total annual economic burden estimates were also explored. To account for varying opinions on the value of a QALY, four alternate values of \$250,000, \$200,000, \$100,000 and \$50,000 per QALY were applied to the economic burden of influenza-attributed mortality calculations \[[@pone.0169344.ref016],[@pone.0169344.ref019]\].

Results {#sec010}
=======

Over the five-year observation period, the number of patients in the study population rose for each respiratory season from 5,294,641 patients in 2010 to 5,754,615 patients in 2014 --an increase of nearly 9% ([S2 Table](#pone.0169344.s004){ref-type="supplementary-material"}). The proportion of patients that identified as female increased slightly from 9.0% in 2010 to 9.7% in 2014. The proportion of patients aged 65 or older increased as well from 48.2% in 2010 to 53.7% in 2014 (p \<0.0001). Notably, the proportion of patients classified as at high-risk for influenza-related complications averaged 11.0% for the 18 to 49 age group, 36.5% for the 50 to 64 cohort and 49.3% for the 65 and older group, decreasing slightly by 1%, 4%, and 1% for each, respectively, over the five years.

Influenza-attributed outcomes {#sec011}
-----------------------------

Annual mean influenza-attributed outcome estimates averaged over the five year study period were determined to be 10,674 (95% CI 8,661--12,687) for VA ED visits, 2,538 (95% CI 2,112--2,964) for VA hospitalizations, 5,522 (95% CI 4,834--6,210) for all-cause deaths and 3,793 (95% CI 3,375--4,211) for respiratory or circulatory deaths (Tables [1](#pone.0169344.t001){ref-type="table"}--[5](#pone.0169344.t005){ref-type="table"}, [S1](#pone.0169344.s001){ref-type="supplementary-material"} and [S2](#pone.0169344.s002){ref-type="supplementary-material"} Figs). Overall, 4.4% of ED visits were attributed to patients aged 18 to 49, 30.0% by those aged 50 to 64, and 65.6% by those aged 65 and older. Patients aged 18 to 49, and 50 to 64, accounted for 5.0% and 14.9%, respectively, of the observed hospitalizations; the patients aged 65 and older were responsible for the remaining 80.1% of hospitalizations. Only 1.8% of influenza-attributed deaths befell patients aged 18 to 49, while 18.9% befell those aged 50 to 64 and 79.3% aged 65 and older. The proportions of influenza-attributed deaths from all-cause deaths were calculated to be 9.2%, 6.3% and 4.1% for those aged 18 to 49, 50 to 64, and 65 and older, respectively, in the high-risk group. In the low-risk group, the proportions were respectively 0.05%, 0.29% and 0.73% ([Table 5](#pone.0169344.t005){ref-type="table"}).

10.1371/journal.pone.0169344.t001

###### Annual estimates of influenza-attributed ED visits[^1^](#t001fn002){ref-type="table-fn"} by risk and age group averaged over five respiratory seasons.

![](pone.0169344.t001){#pone.0169344.t001g}

  Risk      Age          N           95% CI       Person-periods    Rate per 100,000 person-periods   95% CI           
  --------- ------------ ----------- ------------ ----------------- --------------------------------- -------- ------- -----
  High      18--49       186         132          241               128,037                           146      103     188
  50--64    2,843        2,348       3,339        553,798           513                               424      603     
  65+       6,702        5,608       7,796        1,408,113         476                               398      554     
  *Total*   *9*,*732*    *8*,*087*   *11*,*376*   *2*,*089*,*948*   *466*                             *387*    *544*   
  Low       18--49       291         180          401               1,040,587                         28       17      39
  50--64    354          221         486          964,133           37                                23       50      
  65+       298          172         424          1,445,967         21                                12       29      
  *Total*   *942*        *574*       *1*,*311*    *3*,*450*,*687*   *27*                              *17*     *38*    
  Both      18--49       477         312          642               1,168,625                         41       27      55
  50--64    3,197        2,569       3,825        1,517,931         211                               169      252     
  65+       7,000        5,780       8,220        2,854,080         245                               203      288     
  *Total*   *10*,*674*   *8*,*661*   *12*,*687*   *5*,*540*,*636*   *193*                             *156*    *229*   

Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

^1^Events included here are those with a principal diagnosis of underlying respiratory or circulatory conditions (ICD-9-CM codes 390--519).

10.1371/journal.pone.0169344.t002

###### Annual estimates of influenza-attributed hospitalizations[^1^](#t002fn002){ref-type="table-fn"} by risk and age group averaged over five respiratory seasons.

![](pone.0169344.t002){#pone.0169344.t002g}

  Risk      Age         N           95% CI      Person-periods    Rate per 100,00 person-periods   95% CI           
  --------- ----------- ----------- ----------- ----------------- -------------------------------- -------- ------- -----
  High      18--49      127         110         143               128,037                          99       86      112
  50--64    374         301         446         553,798           67                               54       81      
  65+       2,029       1,706       2,351       1,408,113         144                              121      167     
  *Total*   *2*,*529*   *2*,*118*   *2*,*940*   *2*,*089*,*948*   *121*                            *101*    *141*   
  Low       18--49      1           0           3                 1,040,587                        0        0       0
  50--64    3           0           10          964,133           0                                0        1       
  65+       4           0           12          1,445,967         0                                0        1       
  *Total*   *9*         *0*         *24*        *3*,*450*,*687*   *0*                              *0*      *1*     
  Both      18--49      128         110         145               1,168,625                        11       9       12
  50--64    377         299         456         1,517,931         25                               20       30      
  65+       2,033       1,702       2,363       2,854,080         71                               60       83      
  *Total*   *2*,*538*   *2*,*112*   *2*,*964*   *5*,*540*,*636*   *46*                             *38*     *53*    

Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

^1^Events included here are those with a principal diagnosis of underlying respiratory or circulatory conditions (ICD-9-CM codes 390--519).

10.1371/journal.pone.0169344.t003

###### Annual estimates of influenza-attributed all-cause mortality by risk and age group averaged over five respiratory seasons.

![](pone.0169344.t003){#pone.0169344.t003g}

  Risk      Age         N           95% CI      Person-periods    Rate per 100,000 person-periods   95% CI           
  --------- ----------- ----------- ----------- ----------------- --------------------------------- -------- ------- ----
  High      18--49      100         91          109               128,037                           78       71      85
  50--64    1,017       898         1,137       553,798           184                               162      205     
  65+       3,940       3,485       4,394       1,408,113         280                               247      312     
  *Total*   *5*,*057*   *4*,*474*   *5*,*641*   *2*,*089*,*948*   *242*                             *214*    *270*   
  Low       18--49      1           0           2                 1,040,587                         0        0       0
  50--64    23          17          29          964,133           2                                 2        3       
  65+       441         343         538         1,445,967         30                                24       37      
  *Total*   *465*       *360*       *570*       *3*,*450*,*687*   *13*                              *10*     *17*    
  Both      18--49      101         91          111               1,168,625                         9        8       10
  50--64    1,041       915         1,166       1,517,931         69                                60       77      
  65+       4,380       3,828       4,933       2,854,080         153                               134      173     
  *Total*   *5*,*522*   *4*,*834*   *6*,*210*   *5*,*540*,*636*   *100*                             *87*     *112*   

Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

10.1371/journal.pone.0169344.t004

###### Annual estimates of influenza-attributed mortality adjusted for respiratory or circulatory cause of death by risk and age group averaged over five respiratory seasons.

![](pone.0169344.t004){#pone.0169344.t004g}

  Risk      Age         N           95% CI      Person-periods    Rate per 100,000 person-periods   95% CI           
  --------- ----------- ----------- ----------- ----------------- --------------------------------- -------- ------- ----
  High      18--49      38          34          42                128,037                           30       27      33
  50--64    516         455         577         553,798           93                                82       104     
  65+       2,786       2,513       3,060       1,408,113         198                               178      217     
  *Total*   *3*,*341*   *3*,*003*   *3*,*679*   *2*,*089*,*948*   *160*                             *144*    *176*   
  Low       18--49      10          8           12                1,040,587                         1        1       1
  50--64    9           6           13          964,133           1                                 1        1       
  65+       432         358         506         1,445,967         30                                25       35      
  *Total*   *452*       *372*       *532*       *3*,*450*,*687*   *13*                              *11*     *15*    
  Both      18--49      49          43          54                1,168,625                         4        4       5
  50--64    526         461         590         1,517,931         35                                30       39      
  65+       3,219       2,871       3,566       2,854,080         113                               101      125     
  *Total*   *3*,*793*   *3*,*375*   *4*,*211*   *5*,*540*,*636*   *68*                              *61*     *76*    

Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

10.1371/journal.pone.0169344.t005

###### Annual estimates of influenza-attributed all-cause mortality and influenza-attributed mortality adjusted for respiratory or circulatory cause of death as the proportion of all deaths by risk and age group averaged over five respiratory seasons.

![](pone.0169344.t005){#pone.0169344.t005g}

  Risk      Age         N, Influenza Attributed Deaths   N, All Deaths   Proportion (%) of All          
  --------- ----------- -------------------------------- --------------- ----------------------- ------ ------
  High      18--49      100                              38              1,086                   9.21   3.50
  50--64    1,017       516                              16,062          6.33                    3.21   
  65+       3,940       2,786                            97,028          4.06                    2.87   
  *Total*   *5*,*057*   *3*,*341*                        *114*,*176*     4.43                    2.93   
  Low       18--49      1                                10              2,214                   0.05   0.45
  50--64    23          9                                7,986           0.29                    0.11   
  65+       441         432                              60,068          0.73                    0.72   
  *Total*   *465*       *452*                            *70*,*268*      0.66                    0.64   
  Both      18--49      101                              49              3,299                   3.06   1.49
  50--64    1,041       526                              24,048          4.33                    2.19   
  65+       4,380       3,219                            157,096         2.79                    2.05   
  *Total*   *5*,*522*   *3*,*793*                        *184*,*444*     2.99                    2.06   

Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

Cost per influenza-attributed encounter {#sec012}
---------------------------------------

Annual mean estimates of direct medical costs for influenza-attributed ED visits averaged over the five year study period were similar across both risk and age groups, ranging from \$592 in the high-risk 65 and older age group to \$568 in the low-risk 50 to 64 age group ([Table 6](#pone.0169344.t006){ref-type="table"}). For hospitalizations without extended care, the mean direct medical costs increased across age groups for both the high- and low-risk groups. In the high-risk group, the means were \$13,673, \$14,623 and \$14,839 for those aged 18 to 49, 50 to 64 and 65 and older, respectively. In the low-risk group, the respective means were \$10,872, \$13,705 and \$14,723. The mean direct medical costs varied across both risk and age groups for hospitalizations with extended care, ranging from \$49,058 in the high-risk 18 to 49 age group to \$73,233 in the low-risk 50 to 64 age group. The means were highest for the 50 to 64 age groups in both risk categories.

10.1371/journal.pone.0169344.t006

###### Annual estimates of influenza-attributed direct medical costs for healthcare encounters by risk and age group in US Dollars averaged over five respiratory seasons.

![](pone.0169344.t006){#pone.0169344.t006g}

  Risk     Age      ED Visit   Hospitalization Only   Hospitalization with Extended Care                                                
  -------- -------- ---------- ---------------------- ------------------------------------ -------- -------- -------- -------- -------- --------
  High     18--49   574        570                    577                                  13,673   12,959   14,386   49,058   18,164   79,951
  50--64   571      570        573                    14,623                               14,400   14,846   70,701   63,923   77,480   
  65+      592      591        593                    14,839                               14,720   14,958   63,921   61,309   66,534   
  Low      18--49   569        567                    571                                  10,872   10,301   11,442   61,688   37,830   85,545
  50--64   568      566        570                    13,705                               13,339   14,072   73,233   64,085   82,381   
  65+      590      589        592                    14,723                               14,454   14,992   60,526   55,570   65,482   

Ninety six percent of influenza-attributed hospitalizations resulted in a discharge to home or death, while the remaining 4% were followed by extended care at rehabilitation and/or skilled nursing facilities. The mean length of stay averaged over the five year study period for hospitalizations without extended care ranged from 4 to 6 days across the risk and age groups; for hospitalizations with extended care, the mean length of stay ranged from 31 days in the high-risk 18 to 49 age group to 50 days in the low-risk 50 to 64 age group ([Table 7](#pone.0169344.t007){ref-type="table"}).

10.1371/journal.pone.0169344.t007

###### Mean length of stay for hospitalizations without and with extended care[^1^](#t007fn001){ref-type="table-fn"} by risk and age group in days averaged over five respiratory seasons.

![](pone.0169344.t007){#pone.0169344.t007g}

  Risk     Age      Hospitalization Only   Hospitalization with Extended Care                                
  -------- -------- ---------------------- ------------------------------------ ----- ------- ---- ---- ---- ----
  High     18--49   1,368                  4.5                                  4.3   4.7     11   31   7    56
  50--64   14,724   4.9                    4.9                                  5     393     47   41   53   
  65+      47,811   5.2                    5.2                                  5.3   1,984   41   39   44   
  Low      18--49   1,575                  3.8                                  3.7   4       15   35   18   52
  50--64   5,370    4.8                    4.7                                  4.9   110     50   41   59   
  65+      10,114   5.4                    5.3                                  5.5   453     43   38   48   

^1^Events included here are those with a principal diagnosis of underlying influenza and pneumonia (ICD-9-CM codes 480--487).

Economic burden of seasonal influenza epidemics in the VA population {#sec013}
--------------------------------------------------------------------

Projected annual estimates of lost productivity for influenza-attributed ED visits, hospitalizations, hospitalizations with extended care and all-cause mortality averaged over the five year study period were \$590 (95% CI \$487--693) thousand, \$626 (95% CI \$517--746) thousand, \$197 (95% CI \$143--261) thousand and \$25,758 (95% CI \$22,600--28,909) thousand, respectively ([Table 8](#pone.0169344.t008){ref-type="table"}). While those aged 65 and older carried the majority of the lost productivity burden caused by hospitalizations, hospitalizations with extended care and mortality (56%, 53% and 52%, respectively), those aged 50 to 64 carried the majority of the lost productivity burden caused by ED visits (57%).

10.1371/journal.pone.0169344.t008

###### Annual estimates of lost productivity for influenza-attributed healthcare encounters and all-cause mortality by age group in thousands of US Dollars averaged over five respiratory seasons.

![](pone.0169344.t008){#pone.0169344.t008g}

  Age       ED Visit   Hospitalization Only   Hospitalization with Extended Care   All-cause Mortality                                                                     
  --------- ---------- ---------------------- ------------------------------------ --------------------- ------- ------- ------- ------- ------- ------------ ------------ ------------
  18--49    25.0       17.7                   32.4                                 69.1                  57.7    81.6    10.0    3.5     18.2    1,221        1,100        1,342
  50--64    335        277                    394                                  207                   165     251     82      57      111     11,049       9,712        12,376
  65+       229        192                    267                                  350                   293     413     105     83      132     13,488       11,788       15,191
  *Total*   *590*      *487*                  *693*                                *626*                 *517*   *746*   *197*   *143*   *261*   *25*,*758*   *22*,*600*   *28*,*909*

Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

Projected annual estimates of direct medical costs for influenza-attributed ED visits, hospitalizations, and hospitalizations with extended care averaged over the five year study period were \$6.2 (95% CI \$5.1--7.4) million, \$36.1 (95% CI \$29.8--42.7) million and \$5.5 (95% CI \$4.4--6.8) million, respectively ([Table 9](#pone.0169344.t009){ref-type="table"}). Overall, 4.4% of ED visit costs were accounted for by those aged 18 to 49, 29.2% by those aged 50 to 64, and 66.4% by those aged 65 and older. For hospitalizations without extended care costs, patients aged 18 to 49 and those aged 50 to 64 accounted for 4.7% and 15.1%, and those aged 65 and older accounted for 80.2%. Finally, 2.3% of hospitalizations with extended care costs were accounted for by those aged 18 to 49, 4.0% by those aged 50 to 64, and 93.7% by those aged 65 and older.

10.1371/journal.pone.0169344.t009

###### Annual estimates of influenza-attributed direct medical costs for healthcare encounters by risk and age group in thousands of US Dollars averaged over five respiratory seasons.

![](pone.0169344.t009){#pone.0169344.t009g}

  Risk      Age         ED Visit    Hospitalization Only   Hospitalization with Extended Care                                                                 
  --------- ----------- ----------- ---------------------- ------------------------------------ ------------ ------------ ----------- ----------- ----------- -----
  High      18--49      107         75                     139                                  1,702        1,397        2,016       125         40          229
  50--64    1,623       1,338       1,913                  5,425                                4,300        6,568        211         153         276         
  65+       3,968       3,314       4,623                  28,909                               24,112       33,765       5,168       4,167       6,232       
  *Total*   *5*,*698*   *4*,*728*   *6*,*675*              *36*,*036*                           *29*,*808*   *42*,*350*   *5*,*503*   *4*,*361*   *6*,*737*   
  Low       18--49      166         102                    229                                  11           0            34          1           0           2
  50--64    201         125         277                    39                                   0            135          9           0           35          
  65+       176         101         251                    57                                   0            175          6           0           20          
  *Total*   *542*       *328*       *757*                  *107*                                *0*          *344*        *16*        *0*         *58*        
  Both      18--49      272         177                    368                                  1,712        1,397        2,050       126         40          232
  50--64    1,824       1,463       2,190                  5,465                                4,300        6,703        220         153         311         
  65+       4,143       3,416       4,874                  28,966                               24,112       33,940       5,174       4,167       6,253       
  *Total*   *6*,*240*   *5*,*056*   *7*,*432*              *36*,*143*                           *29*,*808*   *42*,*693*   *5*,*520*   *4*,*361*   *6*,*796*   

Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

The annual monetary value of QALYs lost caused by influenza-attributed all-cause deaths averaged over the five year study period amounted to \$1.1 (95% CI \$1.0--1.2) billion ([Table 10](#pone.0169344.t010){ref-type="table"}). The proportion of the monetized QALY loss across risk and age groups was highest for those aged 50 to 64 (71.5% for high-risk and 82.3% for low-risk), followed next by those aged 18 to 49 (27.9% for high and 15.6% for low risk), and smallest for those aged 65 and older (0.53% for high and 2.1% for low). The total annual economic burden, determined by adding the estimates of lost productivity, direct medical costs and the monetary value of QALYs lost, was \$1.2 (95% CI \$1.0--1.3) billion ([Table 11](#pone.0169344.t011){ref-type="table"}).

10.1371/journal.pone.0169344.t010

###### Annual estimates of influenza-attributed life years lost, quality adjusted life years (QALYs) lost and monetary value of QALYs lost by risk and age group in millions of US Dollars averaged over five respiratory seasons.
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  Risk      Age         Life Years Lost   QALYs Lost   Value of QALYs Lost                                                           
  --------- ----------- ----------------- ------------ --------------------- ----------- ----------- ----------- ------- ----------- -----
  High      18--49      2,686             2,444        2,927                 2,009       1,829       2,190       301     274         329
  50--64    6,423       5,672             7,181        5,139                 4,538       5,746       771         681     862         
  65+       25.1        22.2              27.9         38.2                  33.8        42.6        5.7         5.1     6.4         
  *Total*   *9*,*134*   *8*,*138*         *10*,*136*   *7*,*187*             *6*,*401*   *7*,*979*   *1*,*078*   *960*   *1*,*197*   
  Low       18--49      27                0.0          53                    25          0.0         50          3.8     0.0         7.5
  50--64    168         124               211          136                   101         171         20          15      26          
  65+       2.0         1.6               2.5          3.1                   2.4         3.7         0.5         0.4     0.6         
  *Total*   *196*       *126*             *267*        *164*                 *103*       *226*       *25*        *15*    *34*        
  Both      18--49      2,712             2,444        2,981                 2,035       1,829       2,241       305     274         336
  50--64    6,591       5,796             7,393        5,275                 4,639       5,917       791         696     888         
  65+       27.1        23.7              30.4         41.3                  36.2        46.3        6.2         5.4     7.0         
  *Total*   *9*,*330*   *8*,*263*         *10*,*404*   *7*,*351*             *6*,*503*   *8*,*204*   *1*,*103*   *976*   *1*,*231*   

Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

10.1371/journal.pone.0169344.t011

###### Annual estimates of economic burden using direct medical costs, lost productivity and monetary value of quality adjusted life years (QALYs) lost based on all-cause influenza-attributed mortality by age group in millions of US Dollars averaged over five respiratory seasons.

![](pone.0169344.t011){#pone.0169344.t011g}

  Age       Direct Medical Costs   Lost Productivity   Value of QALYs Lost   Total Economic Burden                                                                         
  --------- ---------------------- ------------------- --------------------- ----------------------- ------ ------ ----------- ------- ----------- ----------- ----------- -----------
  18--49    2.1                    1.6                 2.6                   1.3                     1.2    1.5    305         274     336         309         277         340
  50--64    7.5                    5.9                 9.2                   12                      10     13     791         696     888         810         712         910
  65+       38                     32                  45                    14                      12     16     6.2         5.4     7.0         59          49          68
  *Total*   *48*                   *39*                *57*                  *27*                    *24*   *31*   *1*,*103*   *976*   *1*,*231*   *1*,*178*   *1*,*038*   *1*,*318*

Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

Sensitivity analyses {#sec014}
--------------------

Using a combination of the lowest valuation of a QALY and respiratory or circulatory causes of death, the total annual economic burden amounted to \$251 (95% CI \$217--285) million. Alternatively, when using all-cause mortality and the highest valuation of a QALY, the estimate totaled \$1.9 (95% CI \$1.7--2.1) billion ([Table 12](#pone.0169344.t012){ref-type="table"}).

10.1371/journal.pone.0169344.t012

###### Sensitivity analysis to estimate the annual economic burden using direct medical costs, lost productivity and monetary value of quality adjusted life years (QALYs) lost for different monetary values per QALY by all-cause and respiratory or circulatory cause of death adjusted influenza-attributed mortality and age group in millions of US Dollars.

![](pone.0169344.t012){#pone.0169344.t012g}

  Mortality   Age         \$250,000 per QALY   \$200,000 per QALY   \$150,000 per QALY   \$100,000 per QALY   \$50,000 per QALY                                                                                       
  ----------- ----------- -------------------- -------------------- -------------------- -------------------- ------------------- ----------- ----------- ----------- ------- ------- ------- ------- ------- ------- -----
  All-cause   18--49      512                  460                  564                  410                  369                 452         309         277         340     207     186     228     105     94      116
  50--64      1,338       1,176                1,502                1,074                944                  1,206               810         712         910         547     480     614     283     248     318     
  65+         63          53                   73                   61                   51                   70                  59          49          68          57      48      66      55      46      63      
  *Total*     *1*,*913*   *1*,*689*            *2*,*139*            *1*,*545*            *1*,*364*            *1*,*728*           *1*,*178*   *1*,*038*   *1*,*318*   *810*   *713*   *908*   *443*   *388*   *498*   
  Adjusted    18--49      257                  223                  290                  206                  179                 233         155         135         175     104     91      118     54      46      61
  50--64      679         595                  764                  546                  478                  615                 413         362         465         280     245     315     147     128     166     
  65+         56          48                   65                   55                   46                   63                  53          45          62          52      44      60      50      42      59      
  *Total*     *992*       *866*                *1*,*119*            *807*                *704*                *911*               *621*       *542*       *702*       *436*   *379*   *494*   *251*   *217*   *285*   

Discussion {#sec015}
==========

Building on previously published research methods for estimating influenza-attributed urgent healthcare utilization (ED visits and hospitalizations), mortality and costs, this investigation presents an up-to-date assessment of the annual seasonal influenza epidemic burden in the US Veterans Affairs population. As the largest integrated healthcare system in the US, services provided to Veterans at VA can be followed across the care continuum from the non-urgent outpatient clinic to the ED and subsequent hospitalization, as well as post-discharge extended care in rehabilitation and nursing facilities. The analytical dataset used here therefore encompasses the majority of a patient's VA healthcare and costs. We found 10,674 VA ED visits with costs amounting to \$6.2 million, 2,538 VA hospitalizations with costs amounting to \$41.7 million and 5,522 all-cause deaths with monetary losses amounting to \$1.1 billion averaged over the five year study period from 2010 to 2014. Combined, these result in an estimated total annual influenza-attributed societal burden of \$1.2 billion.

Consistent with previously reported results on the general US population, the annual burden of illness caused by seasonal influenza virus infections varied by both risk and age groups and was found to be greatest for those aged 65 and older and at high-risk for complications as based on the presence of certain co-existing medical conditions \[[@pone.0169344.ref001]--[@pone.0169344.ref007]\]. While ED visits and costs were closer among the three age groups than the other outcome event categories, overall, they differed greatly by risk, with those aged 65 and older at high-risk accounting for more of the visits than those aged 18 to 49 at low-risk. Similar findings have been reported by Schanzer and colleagues for the Canadian population \[[@pone.0169344.ref020]\]. The majority of the hospitalizations and deaths occurred for patients aged 65 and older, regardless of risk stratification; thus, most of the hospitalization costs and productivity losses were incurred by those aged 65 and older. However, the monetary value of QALYs lost was considerably smaller for this group than for both the 18 to 49 and 50 to 64 age groups. Overall, premature death was found to be the largest driver of costs, followed by hospitalization.

Limitations {#sec016}
-----------

First, the negative-binomial model used in our analysis was thought to be most appropriate for the over-dispersed data under study and is otherwise similar to the Serfling-Poisson model that has been employed more widely for these types of estimations. Limitations of these methods have been described previously and include (1) the accuracy of identifying outcome events based on the presence of a principal diagnosis code from an observed healthcare encounter, which may not account for influenza's contribution to prompt an individual to seek urgent or emergent care for other conditions or events that are therefore coded as the primary diagnosis; (2) the dependence on coding practices to identify observed outcome events, which may be influenced by a lack of coding resources (e.g. time and skill); and (3) the attribution of all excess outcomes to influenza when confounding, such as the presence of other respiratory viruses like the human metapneumovirus, is possible and may result in an over-estimation of the outcome events \[[@pone.0169344.ref002]--[@pone.0169344.ref007],[@pone.0169344.ref020]--[@pone.0169344.ref021]\]. In addition, our estimation of underlying respiratory or circulatory deaths attributable to influenza, although based on a large random sample, is potentially susceptible to bias as we have not verified that the sample is representative of all VA deaths. Lastly, outliers in the cost data were excluded here in order to mitigate our concerns surrounding the impact that erroneous data and rare-but-extreme values may have on the estimates.

Second, it is difficult to compare the results found through this analysis directly with those reported in previously published studies. The US Veterans Affairs population differs from the US general population in terms not only of size (and growth over time), but in age, gender, and health status \[[@pone.0169344.ref008]\]. Furthermore, the healthcare systems differ in terms of organization and cost across populations under study. The estimates are reported as annual means over a five-year observation period from 2010 to 2014; many of the related earlier studies were performed with data through respiratory season 2010 only and not from the VA population \[[@pone.0169344.ref002]--[@pone.0169344.ref007]\].

Third, our methods for cost accounting were more conservative than some of the previous similar studies. Most notably, costs were limited to the day of an ED visit and the acute or extended care portion of a hospitalization and discharge. Others, such as Molinari and colleagues, have used a window of two weeks prior to and up to 30 days following discharge for these calculations, as well as direct medical costs associated with an outcome of death \[[@pone.0169344.ref005]\]. Additionally, VA cost data represent actual expense figures, not insurance claims, which have been shown to be lower than the cost paid by CMS for similar services \[[@pone.0169344.ref022]--[@pone.0169344.ref024]\]. Also, our healthcare encounter data are partial, including those that occurred at VA facilities but not those at non-VA facilities \[[@pone.0169344.ref025]\]. In contrast, our mortality data are complete. As such, it is likely that our results underestimate the influenza-attributed healthcare encounters that Veterans experience, while they over-estimate the number of influenza-attributed deaths. Finally, VA-specific influenza surveillance data, cause of death and VA-specific utility values for calculating QALYs lost were not available when these analyses were performed. Furthermore, the proportion of employed hospitalized Veterans may be lower than the average we used, leading to a possible over-estimation of the economic burden; however, we did not include wages lost by the Veterans' caregivers, which may, conversely, lead to an under-estimation of the economic burden.

Conclusion {#sec017}
==========

Using five respiratory seasons of data, this study provided an assessment of the burden of influenza epidemics in the US Veterans Affairs population. Over the study period we estimated over 13,000 VA influenza-attributed healthcare encounters, more than 5,000 influenza-attributed deaths, \$48 million in direct medical costs to VA and a projected cost to society of \$1.2 billion occur each year. Future research efforts to evaluate the impact of immunization on this burden and identify opportunities by which to enhance prevention efforts for this population are warranted.
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